192 related articles for article (PubMed ID: 33058894)
1. Improved Prediction of the Drug-Drug Interactions of Pemafibrate Caused by Cyclosporine A and Rifampicin via PBPK Modeling: Consideration of the Albumin-Mediated Hepatic Uptake of Pemafibrate and Inhibition Constants With Preincubation Against OATP1B.
Park JE; Shitara Y; Lee W; Morita S; Sahi J; Toshimoto K; Sugiyama Y
J Pharm Sci; 2021 Jan; 110(1):517-528. PubMed ID: 33058894
[TBL] [Abstract][Full Text] [Related]
2. Plasma concentrations of pemafibrate with co-administered drugs predicted by physiologically based pharmacokinetic modeling in virtual populations with renal/hepatic impairment.
Ogawa SI; Shimizu M; Yamazaki H
Xenobiotica; 2020 Sep; 50(9):1023-1031. PubMed ID: 31900032
[TBL] [Abstract][Full Text] [Related]
3. Cluster Gauss-Newton method analyses of PBPK model parameter combinations of coproporphyrin-I based on OATP1B-mediated rifampicin interaction studies.
Yoshikado T; Aoki Y; Mochizuki T; Rodrigues AD; Chiba K; Kusuhara H; Sugiyama Y
CPT Pharmacometrics Syst Pharmacol; 2022 Oct; 11(10):1341-1357. PubMed ID: 35945914
[TBL] [Abstract][Full Text] [Related]
4. Biomarker-Informed Model-Based Risk Assessment of Organic Anion Transporting Polypeptide 1B Mediated Drug-Drug Interactions.
Kimoto E; Costales C; West MA; Bi YA; Vourvahis M; David Rodrigues A; Varma MVS
Clin Pharmacol Ther; 2022 Feb; 111(2):404-415. PubMed ID: 34605015
[TBL] [Abstract][Full Text] [Related]
5. Increased plasma concentrations of an antidyslipidemic drug pemafibrate co-administered with rifampicin or cyclosporine A in cynomolgus monkeys genotyped for the organic anion transporting polypeptide 1B1.
Ogawa SI; Shimizu M; Kamiya Y; Uehara S; Suemizu H; Yamazaki H
Drug Metab Pharmacokinet; 2020 Aug; 35(4):354-360. PubMed ID: 32601018
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic account of distinct change in organic anion transporting polypeptide 1B (OATP1B) substrate pharmacokinetics during OATP1B-mediated drug-drug interactions using physiologically-based pharmacokinetic modeling.
Hegde PV; Morse BL
Drug Metab Dispos; 2024 May; ():. PubMed ID: 38740464
[TBL] [Abstract][Full Text] [Related]
7. Physiologically-based pharmacokinetic model-based translation of OATP1B-mediated drug-drug interactions from coproporphyrin I to probe drugs.
Mochizuki T; Aoki Y; Yoshikado T; Yoshida K; Lai Y; Hirabayashi H; Yamaura Y; Rockich K; Taskar K; Takashima T; Chu X; Zamek-Gliszczynski MJ; Mao J; Maeda K; Furihata K; Sugiyama Y; Kusuhara H
Clin Transl Sci; 2022 Jun; 15(6):1519-1531. PubMed ID: 35421902
[TBL] [Abstract][Full Text] [Related]
8. Calibrating the In Vitro-In Vivo Correlation for OATP-Mediated Drug-Drug Interactions with Rosuvastatin Using Static and PBPK Models.
Sane R; Cheung KWK; Kovács P; Farasyn T; Li R; Bui A; Musib L; Kis E; Plise E; Gáborik Z
Drug Metab Dispos; 2020 Dec; 48(12):1264-1270. PubMed ID: 33037044
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic Determinants of Daprodustat Drug-Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B-CYP2C8 Interplay.
Bi YA; Jordan S; King-Ahmad A; West MA; Varma MVS
Clin Pharmacol Ther; 2024 Jun; 115(6):1336-1345. PubMed ID: 38404228
[TBL] [Abstract][Full Text] [Related]
10. Quantitative Analyses of Hepatic OATP-Mediated Interactions Between Statins and Inhibitors Using PBPK Modeling With a Parameter Optimization Method.
Yoshikado T; Yoshida K; Kotani N; Nakada T; Asaumi R; Toshimoto K; Maeda K; Kusuhara H; Sugiyama Y
Clin Pharmacol Ther; 2016 Nov; 100(5):513-523. PubMed ID: 27170342
[TBL] [Abstract][Full Text] [Related]
11. Hepatic OATP1B zonal distribution: Implications for rifampicin-mediated drug-drug interactions explored within a PBPK framework.
Hartauer M; Murphy WA; Brouwer KLR; Southall R; Neuhoff S
CPT Pharmacometrics Syst Pharmacol; 2024 Jun; ():. PubMed ID: 38898552
[TBL] [Abstract][Full Text] [Related]
12. Modelled plasma concentrations of pemafibrate with co-administered typical cytochrome P450 inhibitors clopidogrel, fluconazole or clarithromycin predicted by physiologically based pharmacokinetic modelling in virtual populations.
Ogawa SI; Shimizu M; Yamazaki H
Xenobiotica; 2020 Dec; 50(12):1413-1422. PubMed ID: 32628085
[TBL] [Abstract][Full Text] [Related]
13. Physiologically-based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B.
Nakayama S; Toshimoto K; Yamazaki S; Snoeys J; Sugiyama Y
CPT Pharmacometrics Syst Pharmacol; 2023 Oct; 12(10):1461-1472. PubMed ID: 37667529
[TBL] [Abstract][Full Text] [Related]
14. Pitavastatin as an in vivo probe for studying hepatic organic anion transporting polypeptide-mediated drug-drug interactions in cynomolgus monkeys.
Takahashi T; Ohtsuka T; Yoshikawa T; Tatekawa I; Uno Y; Utoh M; Yamazaki H; Kume T
Drug Metab Dispos; 2013 Oct; 41(10):1875-82. PubMed ID: 23929936
[TBL] [Abstract][Full Text] [Related]
15. Experimental and Modeling Evidence Supporting the
Izumi S; Nozaki Y; Lee W; Sugiyama Y
Drug Metab Dispos; 2022 May; 50(5):541-551. PubMed ID: 35241487
[TBL] [Abstract][Full Text] [Related]
16. [Development of Prediction Methods for Drug-Drug Interactions Based on the Construction of Physiologically Based Pharmacokinetic Models for Hepatic OATP Substrate Drugs and Endogenous Substrates].
Yoshikado T
Yakugaku Zasshi; 2023; 143(1):11-19. PubMed ID: 36596534
[TBL] [Abstract][Full Text] [Related]
17. Expanded Physiologically-Based Pharmacokinetic Model of Rifampicin for Predicting Interactions With Drugs and an Endogenous Biomarker via Complex Mechanisms Including Organic Anion Transporting Polypeptide 1B Induction.
Asaumi R; Menzel K; Lee W; Nunoya KI; Imawaka H; Kusuhara H; Sugiyama Y
CPT Pharmacometrics Syst Pharmacol; 2019 Nov; 8(11):845-857. PubMed ID: 31420941
[TBL] [Abstract][Full Text] [Related]
18. PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3.
Yoshikado T; Toshimoto K; Maeda K; Kusuhara H; Kimoto E; Rodrigues AD; Chiba K; Sugiyama Y
CPT Pharmacometrics Syst Pharmacol; 2018 Nov; 7(11):739-747. PubMed ID: 30175555
[TBL] [Abstract][Full Text] [Related]
19. Coproporphyrin I as an Endogenous Biomarker to Detect Reduced OATP1B Activity and Shift in Elimination Route in Chronic Kidney Disease.
Takita H; Scotcher D; Chu X; Yee KL; Ogungbenro K; Galetin A
Clin Pharmacol Ther; 2022 Sep; 112(3):615-626. PubMed ID: 35652251
[TBL] [Abstract][Full Text] [Related]
20. Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example.
Chen Y; Zhu R; Ma F; Mao J; Chen EC; Choo EF; Sahasranaman S; Liu L
Biopharm Drug Dispos; 2018 Nov; 39(9):420-430. PubMed ID: 30335192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
